Skip to main content
See every side of every news story
Published • loading... • Updated

BioCryst Pharmaceuticals (NASDAQ:BCRX) Given New $13.00 Price Target at JPMorgan Chase & Co.

Summary by MarketBeat
JPMorgan Chase & Co. increased their price target on BioCryst Pharmaceuticals from $12.00 to $13.00 and gave the stock a "neutral" rating in a research report on Wednesday.

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

MarketBeat broke the news in Sioux Falls, United States on Wednesday, September 30, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
News
Feed Dots Icon
For You
Search Icon
Search
Blindspot LogoBlindspotLocal